Replies to post #297295 on Avid Bioservices Inc (CDMO)

[ArchieK]

Agree wholeheartedly. Fantastic work/catch on your part as usual. This is the stuff that helps me ignore the nonsense on here. Something's afoot, I'm banking on it big. Thanks again for posting this, VERY valuable information.

[The Other Guy]

Is there a fee involved in this?

[jakedogman1]

cj where does it say "Senior Author" thanks eom

[biopharm]

Thanks CJ and Cliff Hoyt stands out immediately to me due to his ties to Gilead ....

Now Perkin Elmer is in Hopkinton, MA and I remember we picked up an ex-Gilead employee (actually I thought she was working with Gilead and Peregrine till she updated her linkedin profile..) so Gilead must be laying close attention to Cliff lately. There has been numerous employees between Peregrine and Gilead ....here are some puzzle pieces for anyone interested

Lisa Stepp (ex Gilead ) and she immediately appeared in Hopkinton, MA at Perkin Elmer in October 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117218975


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=120513094

Gilead PI3k patent
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117100403

Forty Sevens Gibbs (20 years at Gilead)
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=120829180

Edyta
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121542756

[jakedogman1]

looks like cliff has been down this road..


http://ir.perkinelmer.com/releasedetail.cfm?releaseid=963858
Pre-existing Immunity and Treatment Outcome with Anti-PD1 in Melanoma

Monday, April 18, 3:00 to 4:00 P.M., AACR Exhibitor Spotlight Theater

Presenters:
Paul Tumeh, MD, Assistant Professor, UCLA Medical Center, Dept. of Medicine Clifford Hoyt, Oncology Fellow, PerkinElmer

Abstract:
Therapies that block the PD-1/PD-L1 axis have shown significant clinical activity in melanoma and other cancers. Recent evidence has shown that pre-existing CD8 T cells infiltrates at the invasive tumor margin of metastatic melanoma are associated with the presence of the PD-1/PD-L1 immune axis and may predict response to therapy. We examined the relationship between site of metastatic disease, local immune response, and treatment outcome in patients with advanced melanoma.

and good vid.. (if you're a nerd)

http://www.sciencemag.org/custom-publishing/webinars/cancer-immunology-charting-course-forward-immunoprofiling